base-metals-investing DENARIUS METALS ANNOUNCES 2025 PRODUCTION RESULTS FOR ITS ZANCUDO PROJECT; EXPIRING 2026 WARRANTS STARTING TO BE EXERCISED
base-metals-investing DENARIUS METALS ANNOUNCES DETAILS FOR THE DECEMBER 31, 2025 INTEREST PAYMENTS ON ITS CONVERTIBLE UNSECURED DEBENTURES
base-metals-investing DENARIUS METALS FILES NATIONAL INSTRUMENT 43-101 TECHNICAL REPORT FOR ITS ZANCUDO PROJECT IN COLOMBIA
base-metals-investing Denarius Metals Announces Details for the November 30, 2025 Interest Payments on Its Convertible Unsecured Debentures
base-metals-investing Denarius Metals Announces Closing of Life Offering and Concurrent Private Placement
base-metals-investing Denarius Signs Option Agreement With Europa Metals to Develop the Toral Zinc-Lead-Silver Project, Leon Province, Northern Spain
base-metals-investing Denarius Announces an Initial Mineral Resource Estimate for Its Polymetallic Lomero-Poyatos Project in Southern Spain
silver-investing Denarius Announces Completion of the In-Fill Drilling Program at Its Polymetallic Lomero-Poyatos Project in Spain
silver-investing Denarius Announces Additional Drill Results From the Ongoing Drilling Program at Its Polymetallic Lomero-Poyatos Project in Spain, Including 25.50 Meters at 0.32% Cu, 0.65% Pb, 1.42% Zn, 43.07 g/t Ag and 4.16 g/t Au; Provides Update on Geophysical Surveys
silver-investing GCM Mining Corp. Acquires 3,430,000 Common Shares in Denarius Metals Corp. and Files Early Warning Report
silver-investing Denarius Announces Additional Drill Results from the Ongoing Drilling Program at Its Polymetallic Lomero-Poyatos Project in Spain, Continuing to Validate the Thickness and Grades of Mineralization from Previous Explorers' Drilling Campaigns
silver-investing Denarius Announces Additional Drill Results From the Ongoing Drilling Program at Its Polymetallic Lomero-Poyatos Project in Spain, Including 2.51% Cu, 0.65% Pb, 3.28% Zn, 49.99 g/t Ag and 6.07 g/t Au Over 6.85 Meters
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK
